Simon Harrison, MBBS, MRCP (UK), PhD, FRCPath (UK), FRACP, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia, highlights the importance of multiple myeloma biomarker analyses in predicting patient responses to treatment and the exciting new approaches which will be discussed at ASH 2020. He focuses on BELLINI, a Phase III study (NCT02755597) of venetoclax in combination with bortezomib and dexamethasone in relapsed/refractory myeloma. A number of genetic abnormalities were identified in the cohort and shown to be predictive of outcomes. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.